AstraZeneca Pharma India Limited

Regd. Office : Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore 560 045

Statement of unaudited financial results for the quarter ended 30 June 2023

					Rs in lakhs except for earnings per share data
Sl No.	**Particulars**	**3 months ended 30/06/2023**	**Previous 3 months ended 31/03/2023**	**Corresponding 3 months ended in the previous year 30/06/2022**	**Year ended 31/03/2023**
		Unaudited	**Refer note 3**	**Unaudited**	**Audited**
1	**Income**				
	a) Revenue from operations	29,546.68	28,470.35	23,233.20	100,297.08
	b) Other income	810.37	799.72	411.42	2,610.18
	Total income	**30,357.05**	**29,270.07**	**23,644.62**	**102,907.26**
2	**Expenses**				
	(a) Cost of materials consumed	1,907.76	2,161.98	1,589.15	8,437.84
	(b) Purchase of stock-in-trade	10,284.95	10,371.27	7,531.44	32,445.69
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(1,134.12)	(2,669.99)	(782.60)	(4,885.80)
	(d) Employee benefit expense	5,497.48	6,685.98	6,837.12	25,910.26
	(e) Depreciation expense	379.79	424.89	459.18	1,626.00
	(f) Allowance for expected credit loss (net)	(22.46)	41.29	99.00	167.03
	(g) Selling, marketing and distribution expense	2,126.61	1,378.72	1,073.50	5,974.17
	(h) Other expenses	4,161.91	4,516.24	4,089.31	15,735.38
	(i) Finance costs	15.35	8.80	18.62	63.32
	Total expenses	**23,217.27**	**22,919.18**	**20,914.72**	**85,473.89**
3	**Profit before exceptional and extraordinary items and tax (1-2)**	**7,139.78**	**6,350.89**	**2,729.90**	**17,433.37**
4	Exceptional items (Refer Note 4)	-	4,022.91	-	4,022.91
5	**Profit before extraordinary items and tax (3-4)**	**7,139.78**	**2,327.98**	**2,729.90**	**13,410.46**
6	Extraordinary items	-	-	-	-
7	**Profit before tax (5-6)**	**7,139.78**	**2,327.98**	**2,729.90**	**13,410.46**
8	**Tax expense**				
	- Current tax	1,746.70	838.18	767.51	3,830.25
	- Deferred tax charge/ (credit)	7.01	(237.32)	(52.87)	(349.04)
	Total tax expense	1,753.71	600.86	714.64	3,481.21
9	**Profit after tax (7-8)**	**5,386.07**	**1,727.12**	**2,015.26**	**9,929.26**
10	**Other comprehensive income/(loss)**				
	A Items that will not be reclassified to profit or loss				
	Re-measurement gains/(losses) on post employment benefit obligations	60.82	(278.74)	(9.45)	(349.35)
	Income tax effect on above	(15.31)	70.15	2.38	87.92
	Other comprehensive income/ (loss), net of income tax	**45.51**	**(208.59)**	**(7.07)**	**(261.43)**
	Total comprehensive income for the period (9+10)	**5,431.58**	**1,518.53**	**2,008.19**	**9,667.82**
11	Paid-up equity share capital (Face value of Rs 2/- per equity share)	500.00	500.00	500.00	500.00
12	Other Equity	-	-	-	58,368.83
13	Earnings per equity share of Rs 2/- each (basic and diluted)	21.54	6.91	8.06	39.72

Price Waterhouse & Co Chartered Accountants LLP
LLPIN AAC-4362
FRN 304026E/E300009
Bengaluru

AstraZeneca Pharma India Limited
Regd. Office : Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore 560 045

Statement of unaudited financial results for the quarter ended 30 June 2023

1 The financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (as amended) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.

2 The Company has identified 'Healthcare Segment' as its only reportable segment in accordance with the requirements of Ind AS 108, 'Operating Segments'. Accordingly no segment information has been provided.

3 The figures for the quarter ended 31 March 2023 are the balancing figures between the audited figures in respect of the full financial year 31 March 2023 and the published unaudited year to date figures up to the third quarter of the respective financial year i.e., 31 December 2022 which were subjected to review by the statutory auditors.

4 Exceptional items for the quarter and year ended 31 March 2023 consists of seperation cost amounting to Rs 1,910.32 and Voluntary Retirement Scheme expenses amounting to Rs 2,112.59.

5 This statement of financial results was reviewed and recommended by the Audit Committee of the Board and subsequently approved by the Board of Directors at their respective meetings held on 14 August 2023. The Statutory auditors of the Company have carried out a limited review of this statement of financial results for the quarter ended 30 June 2023.

By Order of the Board of Directors
For AstraZeneca Pharma India Limited

Sanjeev Kumar Panchal
Managing Director

Place: Bengaluru
Date: 14 August, 2023

Price Waterhouse & Co Chartered Accountants LLP
LLPIN AAC-4362
FRN 304026E/E300009
Bengaluru

AstraZeneca Pharma India Limited

Regd. Office : Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore 560 045

Statement of unaudited financial results for the quarter ended 30 June 2023

				Rs in lakhs except for earnings per share data
Sl No.	Particulars	3 months ended 30/06/2023	Corresponding 3 months ended in the previous year 30/06/2022	Year ended 31/03/2023
		Unaudited	Unaudited	Audited
1	Total income from operations	30,357.05	23,644.62	102,907.26
2	Net profit/(loss) for the period from ordinary activities before tax	7,139.78	2,729.90	13,410.46
3	Net profit/(loss) for the period from ordinary activities after tax	5,386.07	2,015.26	9,929.25
4	Total comprehensive income for the period after tax	5,431.58	2,008.19	9,667.82
5	Equity Share Capital	500.00	500.00	500.00
6	Other Equity	-	-	58,368.83
7	Basic and diluted earnings per share (of Rs 2 each)	21.54	8.06	39.72

Notes:

1 The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results is available on the Stock Exchange websites.(www.nseindia.com, www.bseindia.com) and Company's website (www.astrazeneca.com/india).

2 The financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (as amended) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.

By Order of the Board of Directors
For AstraZeneca Pharma India Limited

Sanjeev Kumar Panchal
Managing Director

Place: Bengaluru
Date: 14 August, 2023